CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 8 enrolled
Drug / intervention
Marijuana +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05485012
NCT05485012Phase 1Completed
CompareCT.gov

Modulation of Drug Intake: Evaluation of Opioid and Cannabinoid Interactions on Drug Self-Administration

Shanna Babalonis, PhD·interventional·Posted Aug 2, 2022·Updated Apr 15, 2026

In Brief

A Phase 1 clinical trial evaluating Marijuana and Opioid for Marijuana Use and Opioid Use. Completed, enrolled 8 participants across 1 site.

Detailed Summary

The primary goals of this study are to examine 1) marijuana modulation of oxycodone self-administration and 2) oxycodone modulation of marijuana self-administration, under controlled conditions and across a range of doses for each drug.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMarijuana Use, Opioid Use
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 1CompletedFinished
2023202420252026
First PostedAug 2, 2022
Enrollment StartAug 3, 2023
Primary CompletionMar 27, 2025
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 3.9 years ago

Interventions

Marijuanadrug

Double-blind administration of marijuana

Opioiddrug

Double-blind administration of an opioid agonist